On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...

Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...

TD Cowen analyst Daniel Brennan maintained a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1 ...

With Election Day merely hours away, contentious conversations at work may be reaching a fever pitch. If this gives you agita ...

Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm ...

The US stock market opened higher on Friday, November 1, fueled by Amazon’s strong third-quarter results. U.S. crude oil rose ...

Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. Starting Jan. 1, the UnitedHealth Group unit plans to ...

Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...